Resistance to Penicillin and Erythromycin in Viridans Streptococcal Bloodstream Isolates from Cancer and Non-Cancer Patients Within 10 Years [3]

Infection Control and Hospital Epidemiology

Volumn 25, Issue 5, 2004, Pages 365-367

  Ondrusova, Adriana ^a   Liskova, Anne ^b   Miklosko, Joseph ^a   Babela, Roberta ^a,c   Krcmery, Vladimir ^c  

^a TRNAVA UNIVERSITY   (Slovakia)

^b Hospital Nitra   (Slovakia)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; ERYTHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANCER PATIENT; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION SENSITIVITY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PREVALENCE; PROPHYLAXIS; RESPIRATORY DISTRESS SYNDROME; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; ERYTHROMYCIN; HUMANS; NEOPLASMS; PENICILLINS; SLOVAKIA; VIRIDANS STREPTOCOCCI;

EID: 2442467904     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/503499     Document Type: Letter

References (14)

1. Krcmery V, et al. Increasing resistance to penicillin in viridans streptococci. Lancet 1995;324:1133.
2. Spanik V, Krcmery V Jr, et al. Penicillin-resistant viridans streptococcal bacteremia in cancer patients after introduction of V-PNC into prophylaxis. Scand J Infect Dis 1997;39:123-129.
3. Kern WV, Hay B, Kern P, Marre R, Arnold R. A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antmicrob Agents Chemother 1994;38:465-472.
4. Bryskier A. Viridans group streptococci: a reservoir of resistant bacteria in oral cavities. Clin Microbiol Infect 2002;8:65-69.
5. King A, Bathgate T, Phillips I. Erythromycin susceptibility of viridans streptococci from normal throat flora of patients treated with azithromycin or clarithromycin. Clin Microbiol Infect 2002;8:85-92.
6. Johnson AP, Warner M, Broughton K, et al. Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000. BMJ 2001;322: 395-396.
7. Jacobs JA, Stobberingh EE. In vitro antimicrobial susceptibility of the S. milleri group (Streptococcus anginosus, Streptococcus constellatus and Streptococcus intermedius). J Antimicrob Chemother 1996;37:371-375.
8. Bantar C, Conigia LF, Relloso S, et al. Species belonging to the Streptococcus milleri group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens. J Clin Microbiol 1996;34:2020-2022.
9. Gomez-Garces JL, Alos J, Cogollos R. Bacteriologic characteristics and antimicrobial susceptibility of 70 clinically significant isolates of Streptococcus milleri group. Diagn Microbiol Infect Dis 1994;19:67-73.
10. Arpin C, Canron MH, Manglen J. Incidence of mefA and mefE gene in viridans group streptococci. Antimicrob Agents Chemother 1999;43:2335-2336.
11. Potgieter E, Cormichael M, Koornhof H, Charkley LJ. In vitro antimicrobial susceptibility of viridans streptococci isolated from blood cultures. Eur J Clin Microbiol Infect Dis 1992;11:543-546.
12. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996;40:891-894.
13. De Azavedo, JCS, Trpeski L, Pong-Porter S, Matsumura S. The Canadian bacterial surveillance network and low DE in vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans streptococci from across Canada. Antimicrob Agents Chemother 1999;43:2299-2301.
14. Harnicarova A, Streharova A, Mitterpachova A, et al. Nosocomial Infections. Trnava, Slovak Republic: University of Trnava; 2002:88.